Resistance of Mycobacterium tuberculosis to Fluoroquinolones among Newly Diagnosed Tuberculosis Cases in Russia

Read full text Summarise with VIRAT
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Valeria Guseva, Platon Eliseev, Irina Vasilyeva, Vadim Testov, Irina Lizinfeld National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russia Introduction: Fluoroquinolones (FQ) are a key class of antituberculosis (TB) drugs used in treatment regimens for both drug-sensitive and drug-resistant TB, including short-term courses. However, resistance of Mycobacterium tuberculosis (MTB) to FQ can reduce the effectiveness of treatment. Objective: To evaluate the prevalence and dynamics of MTB drug resistance to FQ among newly diagnosed TB cases in the Russian Federation between 2023 and 2024. Methods: A retrospective analysis of reporting forms from regions of the Russian Federation was carried out for the period 2023–2024. The prevalence of resistance was calculated using the following formula: (number of resistance cases/total number of newly diagnosed TB cases tested) × 100. In addition, indicators of resistance to isoniazid and rifampicin, as well as combined resistance to rifampicin and FQ, were analyzed. To assess changes in the indicators over time, the absolute and relative growth/decline rates were calculated. The statistical significance of the differences was assessed using the Chi-squared test, with a significance level of P < 0.05. Results: Between 2023 and 2024, the number of newly diagnosed TB cases in the Russian Federation decreased by 9.4%, from 39,856 to 36,104. The proportion of bacteriologically confirmed TB cases remained stable, at 52.5% (20,920 cases) in 2023 and 53.0% (19,124 cases) in 2024 (a difference of +0.5 percentage points; P > 0.05). Meanwhile, the coverage of isoniazid and rifampicin sensitivity testing increased, from 98.2% (20,542 cases) to 98.6% (18,861 cases) (an increase of +0.4%; P < 0.05). In 2024, there was a slight increase in the proportion of cases of isoniazid-resistant TB, rising from 10.7% (2195 cases) in 2023 to 11.8% (2222 cases), an increase of 1.1% (P < 0.05). Against the backdrop of a decline in the overall number of new TB cases, the number of patients with multidrug-resistant (MDR) TB has also decreased. At the same time, the proportion of patients in this category increased by 0.7% (from 34.9% to 35.6%) between 2023 and 2024, but this increase was not statistically significant (P > 0.05). Among this group, drug sensitivity testing for FQ was performed in 95.4% of cases in 2023 (6837 cases) and 95.7% in 2024 (6421 cases), an increase of 0.3% (P > 0.05). The prevalence of FQ resistance was 24.1% in 2023 (1646 cases) and 24.7% in 2024 (1589 cases) (an increase of 0.6%; P > 0.05). Conversely, 75.9% of patients were sensitive to FQ in 2023, a figure which decreased to 72.3% in 2024 (−3.6%), reflecting a slight clinical decrease in sensitivity to FQ. Conclusions: The level of FQ resistance among newly diagnosed MDR-TB cases in the Russian Federation has remained stable at 24%–25%, which highlights the need to strengthen molecular genetic monitoring. The combination of rifampicin resistance and FQ complicates therapy selection, lengthens treatment duration, and negatively affects its effectiveness. Keywords: Drug-resistance, fluoroquinolones, Russia, tuberculosis Conflicts of interest There are no conflicts of interest

Fields of Study & Subjects

Tuberculosis Research and Epidemiology Infectious Diseases and Tuberculosis Antibiotic Resistance in Bacteria

Publication details

Journal / source
International Journal of Mycobacteriology
Volume
15
Issue
Abstract Supplement
Pages
S3–S3
Publication date
1 March 2026
Language
EN